I Made Susila Utama
Tropic And Infectious Disease Division, Internal Medicine Dept, Faculty Of Medicine, Universitas Udayana Prof. I.G.N.G.Ngoerah Hospital

Published : 14 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search
Journal : MEDICINUS

Correlation Between CD4 Level and The Severity of Pneumocystis Pneumonia in Patients with Human Immunodeficiency Virus at RSUP Prof. dr. I.G.N.G. Ngoerah, Denpasar, Bali Aries Hasan Basri; I Made Susila Utama
MEDICINUS Vol. 38 No. 12 (2025): MEDICINUS
Publisher : PT Dexa Medica

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.56951/3b8w1665

Abstract

Pneumocystis jirovecii is an opportunistic fungal pathogen that causes life-threatening cases of pneumocystis pneumonia (PCP) in immunodeficient patients. In patients with human immunodeficiency virus (HIV), the risk of developing PCP increases when the CD4 count <200 cells/μl. This study aimed to determine the correlation between the CD4 level and the degree of severity of pneumocystis pneumonia in HIV patients at RSUP Prof. dr. I.G.N.G. Ngoerah, Denpasar, Bali. A retrospective analysis was conducted on HIV patients diagnosed with PCP between 2020 to 2022 period. The researchsubjects were all PCP-PCR positive patients who were hospitalized at RSUP Prof. dr. I.G.N.G. Ngoerah, Denpasar. The results of the study showed a total of 120 subjects, including 28 (23.3%) male subjects with severe PCP and 11 (9.2%)female subjects with severe PCP. The highest number of cases was found in the age range ages 20‒40 years, with 20 (16.6%) subjects having severe PCP. Regarding treatment status, 23 (19.2%) subjects with severe PCP were pre-HAART(highly active antiretroviral therapy) while 16 (13.3%) subjects were on HAART. The highest proportion of severe PCP cases was found in subjects with a CD4 count of less than 50 cells/μl, totaling 32 subjects (26.6%). The Kruskal-Wallistest was applied to assess the association between the CD4 count categories and PCP severity in HIV patients. The study concluded that there is a significant correlation between CD4 levels and the severity of pneumocystis pneumonia in HIVpatientsat RSUP Prof. dr. I.G.N.G. Ngoerah, Denpasar.
Karakteristik Pasien dan Tata Laksana Infeksi Malaria di RSUP Prof. dr. I.G.N.G. Ngoerah Denpasar Tahun 2019-2023 I Dewa Gede Agung Suta Ariwangsa; Harris Hardian; I Made Susila Utama
MEDICINUS Vol. 38 No. 12 (2025): MEDICINUS
Publisher : PT Dexa Medica

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.56951/1xmve570

Abstract

Introduction: Malaria remains a major public health concern, affecting resident and travellers to endemic areas. Severemalaria is a complication of infection that can lead to poor outcomes when late to be diagnosed. The use of artemisininRESEARCH22 VOL. 38 ISSUE 12, DECEMBER 2025derivatives or artemisinin-based combination therapy (ACT) has been reported to improve outcomes and survival in malaria patients. Methods: This was a descriptive study. Data were collected retrospectively from medical records ofpatients treated at RSUP Prof. dr. I.G.N.G. Ngoerah, Denpasar from 2019 to 2023. Descriptive analyses were conducted to summarize patient's characteristics, infection etiology, malaria severity, and treatment outcomes. Results: A total of37 malaria cases were treated at RSUP Prof. dr. I.G.N.G. Ngoerah, Denpasar between 2019 and 2023. The mean age of patients was 29.85 years, and the majority were male (78.37%). Plasmodium vivax was identified as the most commonetiologic agent, in 19 cases (51.35%), followed by Plasmodium falciparum in 17 cases (45.94%), and Plasmodium malariae in 1 case (2.7%). Severe malaria was diagnosed in 9 cases (24.32%), predominantly caused by P. falciparum (7 cases,94.5%). Jaundice and renal dysfunction were the most frequent clinical findings in severe malaria, seen in 7 (77.77%) and 4 (44.44%) cases, respectively. The most common treatment regimens were 3-day dihydroartemisinin-piperaquine (DHP) plus 14-day primaquine in 10 patients (48.64%), and 3-day DHP plus 1-day primaquine in another 10 patients (27.02%).Intravenous artesunate followed by 3-day DHP and 3-day primaquine was administered to 7 patients (18.91%); artesunate followed by DHP and 1-day primaquine to 1 patient (2.7%), and artesunate followed by DHP alone to 1 patient (2.7%). Nodeaths were reported during treatment. Discussion: Severe malaria was identified in 9 out of 37 cases (24.3%), with P. vivax being the most common malaria species overall. Although severe malaria is typically associated with P. falciparumand P. vivax, this study also reported one severe case caused by P. malariae. Jaundice was the most common clinical presentation, often accompanied by renal impairment. All patients received artemisinin-based combination therapy andachieved complete recovery at the end of treatment. Conclusion: Severe malaria occurred in one-quarter of malariacases, with P. falciparum being the most frequent cause. Jaundice and renal dysfunction were the most common clinical manifestations. All patients recovered and were discharged from the hospital.